244 related articles for article (PubMed ID: 36536332)
1. Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review.
Hurkmans EGE; Brand ACAM; Verdonschot JAJ; Te Loo DMWM; Coenen MJH
BMC Cancer; 2022 Dec; 22(1):1326. PubMed ID: 36536332
[TBL] [Abstract][Full Text] [Related]
2. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
5. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
[TBL] [Abstract][Full Text] [Related]
6. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
8. The genetic vulnerability to cisplatin ototoxicity: a systematic review.
Tserga E; Nandwani T; Edvall NK; Bulla J; Patel P; Canlon B; Cederroth CR; Baguley DM
Sci Rep; 2019 Mar; 9(1):3455. PubMed ID: 30837596
[TBL] [Abstract][Full Text] [Related]
9. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
Fox E; Levin K; Zhu Y; Segers B; Balamuth N; Womer R; Bagatell R; Balis F
Oncologist; 2018 Jul; 23(7):762-e79. PubMed ID: 29445029
[TBL] [Abstract][Full Text] [Related]
10. Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update.
Scott EN; Joseph AA; Dhanda A; Tanoshima R; Brooks B; Rassekh SR; Ross CJD; Carleton BC; Loucks CM
Ther Drug Monit; 2023 Dec; 45(6):714-730. PubMed ID: 37726872
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate for high-grade osteosarcoma in children and young adults.
van Dalen EC; de Camargo B
Cochrane Database Syst Rev; 2009 Jan; (1):CD006325. PubMed ID: 19160278
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate for high-grade osteosarcoma in children and young adults.
van Dalen EC; van As JW; de Camargo B
Cochrane Database Syst Rev; 2011 May; 2011(5):CD006325. PubMed ID: 21563152
[TBL] [Abstract][Full Text] [Related]
13. A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.
Hagleitner MM; Coenen MJ; Gelderblom H; Makkinje RR; Vos HI; de Bont ES; van der Graaf WT; Schreuder HW; Flucke U; van Leeuwen FN; Hoogerbrugge PM; Guchelaar HJ; te Loo DM
Clin Cancer Res; 2015 Aug; 21(15):3436-41. PubMed ID: 25829401
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome.
; ; . PubMed ID: 36982681
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]